Literature DB >> 8978296

Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.

D Chauhan1, S Kharbanda, A Ogata, M Urashima, G Teoh, M Robertson, D W Kufe, K C Anderson.   

Abstract

Fas belongs to the family of type-1 membrane proteins that transduce apoptotic signals. In the present studies, we characterized signaling during Fas-induced apoptosis in RPMI-8226 and IM-9 multiple myeloma (MM) derived cell lines as well as patient plasma cell leukemia cells. Treatment with anti-Fas (7C11) monoclonal antibody (MoAb) induced apoptosis, evidenced by internucleosomal DNA fragmentation and propidium iodide staining, and was associated with increased expression of c-jun early response gene. We also show that anti-Fas MoAb treatment is associated with activation of stress-activated protein kinase (SAPK) and p38 mitogen-activated protein kinase (MAPK); however, no detectable increase in extracellular signal-regulated kinases (ERK1 and ERK2) activity was observed. Because interleukin-6 (IL-6) is a growth factor for MM cells and inhibits apoptosis induced by dexamethasone and serum starvation, we examined whether IL-6 affects anti-Fas MoAb-induced apoptosis and activation of SAPK or p38 MAPK in MM cells. Culture of MM cells with IL-6 before treatment with anti-Fas MoAb significantly reduced both DNA fragmentation and activation of SAPK, without altering induction of p38 MAPK activity. These results therefore suggest that anti-Fas MoAb-induced apoptosis in MM cells is associated with activation of SAPK, and that IL-6 may both inhibit apoptosis and modulate SAPK activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8978296

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  ADAM-9 (MDC-9/meltrin-gamma), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the alpha(v)beta5 integrin.

Authors:  Abdullah Karadag; Min Zhou; Peter I Croucher
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.

Authors:  Michel Jourdan; Thierry Reme; Hartmut Goldschmidt; Geneviève Fiol; Véronique Pantesco; John De Vos; Jean-François Rossi; Dirk Hose; Bernard Klein
Journal:  Br J Haematol       Date:  2009-01-08       Impact factor: 6.998

3.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authors:  Teru Hideshima; Laurence Catley; Hiroshi Yasui; Kenji Ishitsuka; Noopur Raje; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 4.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Authors:  Michal Bar-Natan; Dina Stroopinsky; Katarina Luptakova; Maxwell D Coll; Arie Apel; Hasan Rajabi; Athalia R Pyzer; Kristen Palmer; Michaela R Reagan; Myrna R Nahas; Rebecca Karp Leaf; Salvia Jain; Jon Arnason; Irene M Ghobrial; Kenneth C Anderson; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

Review 6.  Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Authors:  Timothy R Rosean; Van S Tompkins; Guido Tricot; Carol J Holman; Alicia K Olivier; Fenghuang Zhan; Siegfried Janz
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

7.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

Review 8.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

9.  Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6.

Authors:  Flavia Q Pirih; Megan N Michalski; Sun W Cho; Amy J Koh; Janice E Berry; Eduardo Ghaname; Pachiyappan Kamarajan; Edith Bonnelye; Charles W Ross; Yvonne L Kapila; Pierre Jurdic; Laurie K McCauley
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

10.  A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.

Authors:  Mariateresa Fulciniti; Teru Hideshima; Claudine Vermot-Desroches; Samantha Pozzi; Puru Nanjappa; Zhenxin Shen; Nipun Patel; Ernest S Smith; Wei Wang; Rao Prabhala; Yu-Tzu Tai; Pierfrancesco Tassone; Kenneth C Anderson; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.